Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
NCT ID: NCT00289614
Last Updated: 2008-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
350 participants
INTERVENTIONAL
2006-01-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patients With Renal Impairment Undergoing CT
NCT00292487
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
NCT00289029
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
NCT00734357
Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients
NCT01402219
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
NCT00782639
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iopamidol 370 mgI/dL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
* Diagnosed as having diabetes mellitus
Exclusion Criteria
* Unstable diabetes
* Concurrent administration of nephrotoxic drugs
* Undergoing dialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bracco Diagnostics, Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathleen S Bensel, CNMT
Role: STUDY_DIRECTOR
Bracco Diagnostics, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bracco Diagnostics, Inc.
Princeton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IOP 105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.